1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
612832F7AB5DE211B00258670004DAAF0
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/benchmarking-meta-analysis-new-product-bridge-fast-start-patient-assistance-programs
18
19
2035.172.217.174
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25BMR




» Products & Services » » Patient Focused Services » Patient Support Programs

Benchmarking Meta-Analysis of New-Product Bridge and Fast-Start Patient Assistance Programs

ID: POP-335


Features:

7 Info Graphics

7 Data Graphics

79 Metrics

3 Narratives


Pages: 17


Published: 2021


Delivery Format: Shipped


 

License Options:


Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • VIEW TOC AND LIST OF EXHIBITS
New-product bridge and fast-start programs are part of integrated patient support services that accelerate patient access to therapy or drive adherence to treatments supporting better outcomes. These patient assistance programs are critical for uninsured and underinsured patients, as well as those experiencing delays in access due to a lengthy prior authorization process.

This Best Practices, LLC report draws upon 9 of our field benchmarking studies to evaluate the prevalence and impact of bridge and fast-start patient assistance programs. The report spotlights current trends and future directions of bridge and fast-start patient assistance programs supporting new biopharmaceutical products. This report also evaluates the patient support hub services and vendor management used to support these critical programs across the biopharmaceutical industry.

Industries Profiled:
Health Care; Pharmaceutical; Diagnostic; Biotech; Medical Device; Biopharmaceutical; Laboratories; Clinical Research; Manufacturing; Consumer Products; Service; Science; Consulting; Chemical; Public Relations; Technology; Communications; Utilities; Computer Software; Telecommunications; Research; Market Research; Medical; Professional Services; Marketing


Companies Profiled:
Abbott; AbbVie; Actelion; Adamas Pharmaceuticals; ADC Therapeutics; Advanced Accelerator Applications; Advanced Sterilization Products; Aerocrine; AeroGen; Agenus; Agios; Aimmune Therapeutics; Akcea Therapeutics; Alcon; Alexion Pharmaceuticals; Align Technology; Alkem; Alkermes; Allergan; Almirall; Alnylam Pharmaceuticals; Altus Biologics; AMAG Pharmaceuticals; Amgen; Amicus Therapeutics; Amylin; Apellis Pharmaceuticals; Aptus Clinical; Arena Pharmaceuticals; Ascend Therapeutics; Ascensia; Asklepion Pharmaceuticals; Aspen Pharmacare; Astellas; AstraZeneca; Atara Biotherapeutics; Auxilium; Avadel Pharmaceuticals; Avanir; Avant Healthcare; Avantor Performance Materials; Aventis; B. Braun; Baxter International; Bayer; Becton Dickinson; BioDelivery Sciences International; Biofrontera; Biogen; Bionical Solutions; Biosense Webster; Boehringer Ingelheim; Boston Scientific; Bracco Diagnostics Inc.; Braeburn; Bristol-Myers Squibb; BSN medical; Canopy Growth; Cara Therapeutics; CardioDynamics; CareFusion; Cascadia Drug Development Group; Catalent Pharma Solutions; Catalyst Pharmaceuticals; Celgene; Celyad; Centocor Ortho Biotech Inc.; Centurion; Chiesi; Cipla; Cofactor Group; Consensus Orthopedics; CooperVision; Cordis; Covidien; CSL Behring; Cubist Pharmaceuticals; Cutanea Life Sciences; Cytokinetics; Daiichi Sankyo; DBV Tehcnologies; Deciphera Pharmaceuticals; Dendreon Pharmaceuticals LLC; DiaSorin; Dicerna Pharmaceuticals; Dr Reddy's Laboratories; Drager; Eagle Pharmaceuticals; EHOB; Eisai; Eli Lilly and Company; Elixir Pharmaceuticals; EMD Serono; Endo Health Solutions; eNeura Therapeutics; Entelos; Envision Pharma Group; Ethicon; Ethypharm; EyePoint Pharmaceuticals; F1 Oncology; FerGene; Ferozsons Laboratories Limited; Ferring Pharmaceuticals; FleishmanHillard; Forest Laboratories; Foundation Medicine; Frankel Advisory Group LLC; Fresenius Medical Care AG & Co. KGaA; Galderma; Galpha Laboratories; GE Healthcare; Genentech; Genmab; Genzyme; Getz Pharma; Gilead Sciences; GlaxoSmithKline ; Glenmark; Greenwich Biosciences; Grifols; Grünenthal; Guerbet; Halloran Consulting Group; Helsinn; Hikma; HLL Lifecare; Hoffmann-La Roche; Horizon Therapeutics; Human Genome Sciences; IDbyDNA; Idorsia; IMS; Incyte; Indivior; Inspire Pharmaceuticals; Intervet International (part of Schering-Plough); Invive Healthcare; Ipsen; Iridex; Ironwood; Janssen; Joerns Healthcare; Johnson & Johnson; Kadmon Pharmaceuticals; Kala Pharmaceuticals; Kaleo; Karyopharm Therapeutics; KimberlyClark; Kiniksa Pharmaceuticals; Kyowa Kirin; Leica Biosystems; LeMaitre Vascular; LEO Pharma; Lexicon Pharmaceuticals; Lilly; Lumenis; Lundbeck; Lupin; Mallinckrodt; Mayne Pharma; McKesson (Patient Relationship Solutions); Meda Pharmaceuticals; Medacta USA; Medexus Pharmaceuticals; Medicago; Medicure; MedinCell; MEDiSTRAVA; Medivation; Medline; Medrad; Medrobotics; Medtronic; Melinta Therapeutics; Menarini Group; Merck; Merck KGaA; Merck Serono; Micro Labs; Milestone Pharmaceuticals; Mint Pharmaceuticals Inc.; Mirador Global LP; Mission Bio; Monebo Technologies; Monogram Biosciences; MSD; Mylan; Myovant Sciences; Nabriva Therapeutics; Nektar Therapeutics; Nestle Health Science; Neurocrine Biosciences; Nevakar; NexGen Healthcare Communications; Nico ; Nobio; Nonin; Novartis; Novartis Consumer Health; Noven Pharmaceuticals; Noven Therapeuticals; Novo Nordisk; Nuvisan; OncoCyte; Ora; Ortho Biotech; Ortho-Clinical Diagnostics; Osmotica Pharmaceuticals; OTSUKA; Panacea Biotec; PanTheryx; Paratek Pharmaceuticals; Parexel; Patheon; Pfizer; Pharmacyclics; Piramal Group; PLIVA Pharmaceuticals; Prime Global; Prometheus Therapeutics & Diagnostics; Proteus Digital Health; Purdue Pharma; QED Therapeutics; Ranbaxy; RECKITT BENCKISER; Regeneron; Retrophin; Rigel Pharmaceuticals; Roche; Roche Diagnostics; S3 Group; Samumed; Sandoz; Sanofi; Sanofi Genzyme; Sanofi Pasteur; Sanofi-Aventis; Santen; Santhera Pharmaceuticals; Sarah Cannon; Schering-Plough; Scilex Pharmaceuticals; Sebela; Servier; Shionogi Inc.; Shire; Siren Interactive; Sivantos Pte. Ltd.; SK Life Science; Smith & Nephew; Solvay Pharmaceuticals; SomaGenics Inc; Stgilesmedical London & Berlin; Stiefel; Straumann; Stryker; Sumitovant BioPharma; Sunovion; Supernus; Surrozen; Syneos Health; Syros Pharmaceuticals; Takeda Oncology; Takeda Pharmaceuticals; Tecan; TerSera Therapeutics; Tesaro; Teva Neuroscience; Teva Pharmaceutical Industries Ltd; TG Therapeutics; The Medical Affairs Company; The Stem; Theravance; Thermo Fisher Scientific; Think Surgical; Thompson Surgical Instruments; Tokai Pharmaceuticals; UCB Pharma; United BioSource; United Therapeutics; Valeant; Vertex Pharmaceuticals; Victory; Vifor Pharma; ViiV Healthcare; Visioneering Technologies Inc.; Wellspect HealthCare; West 53rd St Digital; Wockhardt; Worldwide Clinical Trials; XACT Robotics; Xanodyne Pharmaceuticals; XG Sciences; Zeiss Pharma; Zimmer Biomet; Zoetis Inc.; Zosano Pharma; ZS Pharma; Zydus Cadila

Study Snapshot

This Best Practices, LLC report draws upon 9 of our benchmarking field studies of over 300 companies probing bridge and other patient assistance programs.

Key topics covered in this report include:

  • Current trends and future directions of bridge assistance programs supporting new biopharmaceutical products
  • Prevalence and impact of bridge programs
  • Bridge programs role during new product introduction
  • Patient support hub vendor management
  • Patient support hub services
  • Pull through framework

Key Findings

Select key insights uncovered from this report are noted below. Detailed findings are available in the full report.

  • Multi-faceted Programs: Deployed by 53% of companies – bridge programs are part of multi-faceted patient support systems that provide upfront and continuous services
  • Risk of Doing Nothing: 92% of organizations consider Patient Support Failures to be a high- or medium-risk pitfall: patients that have difficulty getting started are easily lost for good
  • One of Many: Fast Start Programs are one of 15 patient support services often coordinated through Hubs

Table of Contents

Sr. No.
Topic
Slide No.
I.
Universe of Learning & Field StudiesPg. 3
II.
Business PriorityPg. 5
III.
Overarching InsightsPg. 6
IV.
Bridge Program PrevalencePg. 7
V.
Bridge Impact RatingsPg. 8
VI.
Bridge Programs Have Many FormsPg. 11
VII.
Risk of Failed Patient Support ProgramsPg. 12
VIII.
Patient Hubs & Hub ServicesPg. 13
IX.
Pandemic Stimulates Increase in Bridge ProgramsPg. 15
X.
New Field Roles to Support Fast Start & Reimbursement ProgramsPg. 16

    List of Charts & Exhibits

    • Utilization of bridge programs - Breakdown by therapeutic area
    • Observed impact of listed patient assistance programs in response to the COVID-19 crisis
    • Impact of patient support/assistance programs
    • Frontline tactics to ensure fast early coverage and continued access to treatment for patients already impacted
    • Current and future risk level of each patient pitfall that can derail a new product coming into a crowded market
    • Collaboration with patient hub vendor; Patient support hub offerings
    • Patient support hub packages / services
    • Evolution of patient assistance / support programs during COVID-19 crisis
    • Pull through excellence to support bridge / fast start and other patient programs